Anbio Biotechnology Class A Ordinary Shares (NNNN) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Anbio Biotechnology Class...

    NASDAQ: NNNN · Real-Time Price · USD
    47.85
    0.21 (0.44%)
    At close: Sep 05, 2025, 3:59 PM
    47.00
    -1.78%
    After-hours: Sep 05, 2025, 06:22 PM EDT

    Anbio Biotechnology Class A Ordinary Shares Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 8.19M 6.71M 23.54M 4.43M
    Cost of Revenue
    		 2.3M 3.35M 10.98M 1.89M
    Gross Profit
    		 5.89M 3.36M 12.56M 2.54M
    Operating Income
    		 2M 1.96M 10.2M 2.46M
    Interest Income
    		 337.51K 165.34K 42.24K n/a
    Pretax Income
    		 2.37M 2.25M 10.01M 2.54M
    Net Income
    		 2.37M 2.25M 10.01M 2.54M
    Selling & General & Admin
    		 3.44M 1.27M 2.17M 86.09K
    Research & Development
    		 454.23K 134.7K 200K n/a
    Other Expenses
    		 n/a n/a n/a n/a
    Operating Expenses
    		 3.89M 1.4M 2.37M 86.09K
    Interest Expense
    		 n/a n/a 8K n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 6.19M 4.75M 13.35M 1.97M
    Income Tax Expense
    		 n/a n/a n/a n/a
    Shares Outstanding (Basic)
    		 42.29M 143.89M 143.89M 100M
    Shares Outstanding (Diluted)
    		 42.29M 187.78M 143.89M 100M
    EPS (Basic)
    		 0.06 0.02 0.07 0.03
    EPS (Diluted)
    		 0.06 0.01 0.07 0.03
    EBITDA
    		 2.57M 2.45M 10.03M 2.54M
    EBIT
    		 2.37M 2.25M 10.02M 2.54M
    Depreciation & Amortization
    		 n/a 13.04K 6.25K n/a

    Add to Watchlist